Coeptis Therapeutics (COEP) Competitors $17.50 +0.84 (+5.04%) Closing price 04:00 PM EasternExtended Trading$17.08 -0.43 (-2.43%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. TNXP, OGI, VYGR, AVIR, JBIO, PBYI, HRTX, AARD, SOPH, and SXTCShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Tonix Pharmaceuticals (TNXP), Organigram Global (OGI), Voyager Therapeutics (VYGR), Atea Pharmaceuticals (AVIR), Jade Biosciences (JBIO), Puma Biotechnology (PBYI), Heron Therapeutics (HRTX), Aardvark Therapeutics (AARD), SOPHiA GENETICS (SOPH), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Tonix Pharmaceuticals Organigram Global Voyager Therapeutics Atea Pharmaceuticals Jade Biosciences Puma Biotechnology Heron Therapeutics Aardvark Therapeutics SOPHiA GENETICS China SXT Pharmaceuticals Coeptis Therapeutics (NASDAQ:COEP) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment. Do insiders & institutionals hold more shares of COEP or TNXP? 13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, COEP or TNXP? Coeptis Therapeutics has a beta of -0.57, suggesting that its share price is 157% less volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Do analysts rate COEP or TNXP? Tonix Pharmaceuticals has a consensus target price of $70.00, suggesting a potential upside of 189.14%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer COEP or TNXP? In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 2 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.95 beat Tonix Pharmaceuticals' score of 0.74 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is COEP or TNXP more profitable? Coeptis Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -828.22%. Tonix Pharmaceuticals' return on equity of -57.93% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -201.73% -108.46% Tonix Pharmaceuticals -828.22%-57.93%-51.04% Which has stronger earnings & valuation, COEP or TNXP? Coeptis Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-3.02Tonix Pharmaceuticals$10.09M21.04-$130.04M-$39.47-0.61 SummaryTonix Pharmaceuticals beats Coeptis Therapeutics on 10 of the 15 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.31M$3.09B$5.65B$10.33BDividend YieldN/A2.44%5.79%4.65%P/E Ratio-3.027.9057.5322.55Price / SalesN/A453.76561.59135.97Price / CashN/A44.6837.1160.83Price / Book10.879.7412.416.36Net Income-$10.88M-$52.93M$3.29B$270.97M7 Day Performance26.08%3.87%1.26%0.36%1 Month Performance32.48%7.65%3.84%6.37%1 Year Performance439.79%20.14%61.01%28.46% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.4636 of 5 stars$17.50+5.0%N/A+397.9%$80.31MN/A-3.022TNXPTonix Pharmaceuticals3.4991 of 5 stars$27.12-2.3%$70.00+158.1%+82.4%$237.84M$10.09M-0.6950Analyst RevisionOGIOrganigram Global1.303 of 5 stars$1.76+2.9%N/A+0.6%$235.93M$223.82M35.21860Positive NewsVYGRVoyager Therapeutics4.1887 of 5 stars$4.25+1.0%$13.25+211.7%-29.1%$235.74M$42.58M-2.30100News CoverageAVIRAtea Pharmaceuticals2.1261 of 5 stars$2.97-2.3%$6.00+102.0%-15.2%$235.69MN/A-1.8470JBIOJade Biosciences2.4337 of 5 stars$7.14+1.0%$16.00+124.1%N/A$232.98MN/A-0.2420PBYIPuma Biotechnology4.0204 of 5 stars$4.52-2.6%$7.00+54.9%+84.3%$227.67M$230.50M4.61200Positive NewsHRTXHeron Therapeutics4.0987 of 5 stars$1.24flat$4.50+262.9%-35.4%$227.32M$144.29M-62.00300Positive NewsAARDAardvark Therapeutics3.2694 of 5 stars$10.26+3.1%$32.60+217.7%N/A$222.64MN/A0.0018Analyst ForecastHigh Trading VolumeSOPHSOPHiA GENETICS1.9407 of 5 stars$3.23+1.9%$8.00+147.7%-15.9%$218.28M$65.17M-7.34520SXTCChina SXT Pharmaceuticals1.2578 of 5 stars$1.87+0.3%N/A-67.0%$216.39M$1.74M0.0090Positive NewsGap Up Related Companies and Tools Related Companies Tonix Pharmaceuticals Alternatives Organigram Global Alternatives Voyager Therapeutics Alternatives Atea Pharmaceuticals Alternatives Jade Biosciences Alternatives Puma Biotechnology Alternatives Heron Therapeutics Alternatives Aardvark Therapeutics Alternatives SOPHiA GENETICS Alternatives China SXT Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondWeiss Ratings’ AI stock system — the same model that flagged Apple, Nvidia, and Netflix early — is now flashin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
